409 Shares in Amgen Inc. $AMGN Bought by Winthrop Capital Management LLC

Winthrop Capital Management LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 409 shares of the medical research company’s stock, valued at approximately $114,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Midwest Trust Co acquired a new position in shares of Amgen during the second quarter worth about $22,082,000. FDx Advisors Inc. grew its stake in Amgen by 7.1% during the 2nd quarter. FDx Advisors Inc. now owns 1,056 shares of the medical research company’s stock valued at $295,000 after purchasing an additional 70 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Amgen by 564.7% in the 2nd quarter. Acadian Asset Management LLC now owns 135,128 shares of the medical research company’s stock valued at $37,722,000 after purchasing an additional 114,800 shares in the last quarter. CSM Advisors LLC raised its position in shares of Amgen by 3.8% in the 2nd quarter. CSM Advisors LLC now owns 13,187 shares of the medical research company’s stock valued at $3,682,000 after purchasing an additional 480 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its stake in shares of Amgen by 1.7% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 29,665 shares of the medical research company’s stock valued at $8,283,000 after buying an additional 485 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AMGN. The Goldman Sachs Group dropped their price target on shares of Amgen from $405.00 to $400.00 and set a “buy” rating for the company in a research note on Wednesday. Guggenheim raised their price objective on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday. Wells Fargo & Company boosted their target price on shares of Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Wednesday. Finally, Citigroup lifted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 24th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $308.83.

Amgen Trading Up 1.5%

Amgen stock opened at $320.20 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88. The firm’s 50-day moving average is $289.94 and its 200-day moving average is $288.57. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company has a market cap of $172.42 billion, a P/E ratio of 26.18, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio is 73.57%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.